

**FINAL – FOR RELEASE**

**EDITORIAL CONTACTS:**

Bret Dash, Director of Marketing  
(760) 268-5242  
bdash@genvault.com

## GenVault Receives Four Critical U.S. and E.U. Patent Allowances for Key Biosample Management Technologies

CARLSBAD, Calif., May 20, 2009 – GenVault Corporation is pleased to announce notice of allowance for four key patents in its growing portfolio. US Patent Application #10/005,415, entitled “**Automated Biological Sample Archive for Storage, Retrieval & Analysis of a Large Number of Samples**” and European Patent Application #02776478.6, entitled “**Archive & Analysis System and Method**”, complement the already-awarded US patent US Patent #7,142,987. Taken together, these allowed and awarded patents grant GenVault broad, exclusive, intellectual property coverage in support of its core business: the development and commercialization of consumables, hardware and software for the acquisition, storage and recovery of biological specimens that have been preserved in the dried solid state, to be used for the building and use as biobanks or biorepositories.

GenVault is also pleased to announce notice of allowance of the first of several key patents in its portfolio which cover *novel matrices* to stabilize biospecimens in the air-dried state. The allowed claims in “**Stable Protein Storage and Stable Nucleic Acid Storage in Recoverable Form**”, US Patent Application #11/137,806 and European Patent Application #05754240.9, grant GenVault broad, exclusive intellectual property coverage in support of a range of new products based on biospecimen stabilization in engineered sponge and similar materials. The company feels that this new “elastomeric” matrix offers the promise to be a replacement for filter paper, swabs and a number of other matrices for the collection, shipping and storage of biospecimens, especially in the context of public health and personalized medicine.

“GenVault continues to strengthen its leadership position in the emerging field of efficient and cost effective biosample management with an expanding patent portfolio,” said David Wellis, CEO, GenVault. “Our growth and value strategy includes firmly establishing GenVault’s intellectual property position which enables the company to exclusively market consumables, hardware and software solutions for the efficient transport and banking of biosamples.”

### **About GenVault**

GenVault is the global leader in providing risk free biosample workflow, transport, and storage solutions for genomic medicine, discovery and identification. Today, GenVault is empowering over 150 pharmaceutical companies, medical centers, academic institutions and law enforcement



6190 Corte Del Cedro, Carlsbad, CA 92011

agencies to more fully leverage the rapidly growing genomics industry. As a scalable, reliable and environmentally friendly alternative to traditional freezers and DNA purification systems, the company's dry-state platforms enable the extraction, preservation, recovery, and distribution of DNA at ambient temperatures. Future systems will also accommodate proteins and RNA to provide a comprehensive solution. From GenPlate to the Dynamic Archive, GenVault is continuously developing and refining best practices for DNA sample management and preservation. For more information visit GenVault at [www.genvault.com](http://www.genvault.com).